Author

C. Creasy

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Approach:statistical model· 3 Research Focus:cell type annotation· 2 Assay:ChIP-seq· 2 Assay:bulk RNA-seq· 1 Research Focus:cell-cell communication· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1

Frequent Co-Authors

C. Bernatchez· 3 shared C. Terranova· 2 shared K. Rai· 2 shared M. Maitituoheti· 2 shared M. Tang· 2 shared P. Hwu· 2 shared S. E. Woodman· 2 shared S. Sarkar· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

C. Bernatchez

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Metabolic plasticity of T-cell therapies: multi-omic profiling of interacting human tumor-infiltrating lymphocytes and autologous tumor adoptive cell therapy

M. Martinez-Paniagua, C. Haymaker, J. Robinson, M. Harel, C. Creasy, J. R. T. Adolacion, X. An, M. Fathi, A. Rezvan, M. Kumar, A. Amritkar, S. E. Woodman, R. N. Amaria, T. Geiger, P. Hwu, , N. Varadarajan

This study profiles the metabolic interactions between TILs and autologous tumor cells in ACT, finding that responder TILs are more efficient at fatty acid oxidation under starvation.

bioRxiv · Sep 28, 2022 · PreprintImmunology

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy Resistance

M. Maitituoheti, A. Shi, M. Tang, L.-L. Ho, C. Terranova, K. Galani, E. Keung, C. Creasy, M. Wu, J. Chen, N. Chen, A. Singh, A. Chaudhri, N. Anvar, G. Tarantino, , K. Rai

The paper identifies enhancer-based biomarkers of resistance to anti-PD-1 therapy in melanoma and suggests enhancer blockade combined with ICB as a potential strategy to improve treatment responses.

bioRxiv · Aug 31, 2022 · PreprintCancer Biology

Bivalent and Broad Chromatin Domains Regulate Pro-metastatic Drivers in Melanoma

C. Terranova, M. Tang, M. Maitituoheti, A. Raman, J. Schulz, S. Amin, E. Orouji, K. Tomczak, S. Sarkar, J. Oba, C. Creasy, C.-J. Wu, D. Zhao, K. Chen, L. E. Haydu, , K. Rai

The paper identifies bivalent chromatin states and broad H3K4me3 domains associated with pro-metastatic drivers in melanoma using ChIP-sequencing data from tumor samples and cell lines.

bioRxiv · Aug 1, 2019 · PreprintCancer Biology